Article
Clinical Neurology
Diana A. Roth O'Brien, Sydney M. Kaye, Phillip J. Poppas, Sean S. Mahase, Anjile An, Paul J. Christos, Benjamin Liechty, David Pisapia, Rohan Ramakrishna, A. G. Wernicke, Jonathan P. S. Knisely, Susan C. Pannullo, Theodore H. Schwartz
Summary: This study evaluated the real-world local recurrence of all brain metastasis patients referred for adjuvant stereotactic radiosurgery (SRS) and identified predictors of SRS timing. The timing of SRS was found to be associated with local recurrence rate and LRFS, with receiving SRS within 4 weeks postoperatively potentially reducing the recurrence rate.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Sergej Telentschak, Daniel Ruess, Stefan Grau, Roland Goldbrunner, Niklas von Spreckelsen, Karolina Jablonska, Harald Treuer, Martin Kocher, Maximilian Ruge
Summary: The study retrospectively analyzed 34 patients treated with CK-hSRS, showing good treatment effectiveness with high local control rates but a 12% complication rate.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yongye Chen, Siyuan Qin, Weili Zhao, Qizheng Wang, Ke Liu, Peijin Xin, Huishu Yuan, Hongqing Zhuang, Ning Lang
Summary: This study aimed to develop response prediction models for patients with spinal metastases undergoing stereotactic body radiotherapy (SBRT) by extracting radiomics features from MRI using machine learning algorithms. The results showed that the MRI-based radiomics models have valuable predictive capability for treatment outcomes in these patients.
INSIGHTS INTO IMAGING
(2023)
Article
Oncology
Rodney E. Wegner, Stephen Abel, Randy S. D'Amico, Gautam U. Mehta, Jason Sheehan
Summary: Evidence suggests that receiving immunotherapy within 7 days of SRS treatment may be associated with improved survival rates in melanoma patients with brain metastases.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
J. A. Crouzen, A. L. Petoukhova, M. L. D. Broekman, M. Fiocco, U. J. Fisscher, J. H. Franssen, C. G. M. Gadellaa-van Hooijdonk, M. Kerkhof, M. Kiderlen, M. E. Mast, C. M. van Rij, R. Nandoe Tewarie, M. A. E. van de Sande, P. P. G. van der Toorn, R. Vlasman, M. J. Vos, N. C. M. G. van der Voort van Zyp, R. G. J. Wiggenraad, L. M. Wiltink, J. D. Zindler
Summary: A multicenter prospective randomized study aims to compare the incidence of adverse local events in patients with brain metastases using fractionated stereotactic radiosurgery (fSRS) versus stereotactic radiosurgery (SRS) in one or three fractions. The study aims to reduce the risk of radionecrosis and improve the effectiveness of brain metastases treatment.
Article
Oncology
Michael Yan, Minha Lee, Sten Myrehaug, Chia-Lin Tseng, Jay Detsky, Hanbo Chen, Sunit Das, Collins Yeboah, Nir Lipsman, Leodante Da Costa, Lori Holden, Chinthaka Heyn, Pejman Maralani, Mark Ruschin, Arjun Sahgal, Hany Soliman
Summary: This study aimed to report the outcomes of salvage hypofractionated stereotactic radiosurgery (HSRS) for brain metastases that failed prior HSRS/SRS. The results showed that HSRS can effectively control local failures and has low toxicity rates.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Clinical Neurology
Georgios Mantziaris, Stylianos Pikis, Zhiyuan Xu, Reed Mullen, Juan Alzate, Kenneth Bernstein, Douglas Kondziolka, Zhishuo Wei, Ajay Niranjan, L. Dade Lunsford, Roman Liscak, Jaromir May, Cheng-chia Lee, Huai-che Yang, Francois-Louis Coupe, David Mathieu, Kimball Sheehan, Darrah Sheehan, Joshua D. Palmer, Haley K. Perlow, Selcuk Peker, Yavuz Samanci, Jennifer Peterson, Daniel M. Trifiletti, Matthew J. Shepard, Shahed Elhamdani, Rodney E. Wegner, Herwin Speckter, Wenceslao Hernandez, Ronald E. Warnick, Jason Sheehan
Summary: This retrospective study showed that stereotactic radiosurgery (SRS) is an effective treatment option for intraventricular metastases (IVMs), with a comparable local control rate to SRS for parenchymal brain metastases. However, careful follow-up is needed to detect leptomeningeal spread and hydrocephalus in patients with IVMs.
Review
Oncology
Raphael Bodensohn, Sebastian H. Maier, Claus Belka, Giuseppe Minniti, Maximilian Niyazi
Summary: In the past year, there have been improvements in cancer treatment, especially for cancers that have spread throughout the body. However, treating tumors that spread to the brain, causing brain metastases, is still a challenge. Local treatments like stereotactic radiosurgery are important for addressing brain metastases.
Article
Oncology
Jinghui Pan, Jinsheng Xiao, Changli Ruan, Qibin Song, Lei Shi, Fengjiao Zhuo, Hao Jiang, Xiangpan Li
Summary: Despite promising results shown by deep learning in automated radiotherapy planning, its application to a specific scenario of stereotactic radiosurgery (SRS) for brain metastases using fixed-field intensity modulated radiation therapy (IMRT) on a linear accelerator remains limited. This study aimed to develop and verify a deep learning-guided automated planning protocol tailored for this scenario, which successfully achieved the goal. By using 70 SRS plans for solitary brain metastases, a deep learning-guided automated planning process was established, including steps such as clinical dose prediction facilitated by deep-learning algorithms.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Raees Tonse, Martin C. Tom, Minesh P. Mehta, Manmeet S. Ahluwalia, Rupesh Kotecha
Summary: In modern times, brain metastasis requires multi-modal management and interdisciplinary care. Traditionally, treatment strategies have focused on local treatments alone due to limited efficacy of cytotoxic chemotherapy. However, with the availability of molecular-based therapies with central nervous system penetration, individualized selection of tailored systemic therapies can now be used alongside local treatments. Moreover, the introduction of immune checkpoint inhibitors has further revolutionized the management of brain metastasis patients.
Article
Oncology
Joshua D. Palmer, Haley K. Perlow, Jennifer K. Matsui, Cindy Ho, Rahul N. Prasad, Kevin Liu, Rituraj Upadhyay, Brett Klamer, Joshua Wang, Mark Damante, Jayeeta Ghose, Dukagjin M. Blakaj, Sasha Beyer, John Grecula, Andrea Arnett, Evan Thomas, Arnab Chakravarti, Russell Lonser, Douglas Hardesty, Daniel Prevedello, Roshan Prabhu, James B. Elder, Raju R. Raval
Summary: This study analyzed the effects of pre-operative fractionated stereotactic radiation therapy (FSRT) for brain metastasis. The results showed that pre-operative FSRT had a lower composite endpoint event rate compared to post-operative single fraction stereotactic radiosurgery (SRS), indicating its safety and effectiveness in reducing adverse outcomes. Further prospective validation is needed.
JOURNAL OF NEURO-ONCOLOGY
(2022)
Article
Clinical Neurology
Adomas Bunevicius, Karen Lavezzo, Leah Shabo, Jesse McClure, Jason P. Sheehan
Summary: The study evaluated the quality of life in patients treated with stereotactic radiosurgery for brain metastases, finding that the quality of life remained largely stable post-treatment. Factors such as the patient's RPA class, upfront whole-brain radiation therapy, and the number of intracranial lesions were identified as independent predictors of post-treatment quality of life deterioration. Additionally, a lower pre-treatment quality of life was associated with shorter survival independently of other clinical and demographic variables.
JOURNAL OF NEUROSURGERY
(2021)
Article
Clinical Neurology
Stylianos Pikis, Adomas Bunevicius, Cheng-Chia Lee, Huai-Che Yang, Brad E. Zacharia, Roman Liscak, Gabriela Simonova, Manjul Tripathi, Narendra Kumar, David Mathieu, Remi Perron, Selcuk Peker, Yavuz Samanci, Jason Gurewitz, Kenneth Bernstein, Douglas Kondziolka, Ajay Niranjan, L. Dade Lunsford, Nikolaos Mantziaris, Jason P. Sheehan
Summary: This multicenter study evaluated the safety and efficacy of stereotactic radiosurgery (SRS) in the management of intracranial prostate cancer metastases. The results showed that SRS was a safe, well-tolerated, and effective treatment option for these patients.
JOURNAL OF NEUROSURGERY
(2022)
Article
Clinical Neurology
Nourou Dine Adeniran Bankole, Adyl Melhaoui, Yasser Arkha, Semmar Afaf, Khalid Bouyakhlef, Mahjouba Boutarbouch, Mohamed Jiddane, Abdeslam El Khamlichi
Summary: This study retrospectively evaluated the outcomes of patients with brain metastases treated with Leksell Gamma Knife stereotactic radiosurgery (GKSR) between 2008 and 2021. The results showed that GKSR provides good overall survival (OS) and better quality of life for patients with single or multiple brain metastases. Tumor stability and retreatment influenced the OS of patients with brain metastases.
WORLD NEUROSURGERY
(2023)
Article
Oncology
Luca Nicosia, Piera Navarria, Valentina Pinzi, Martina Giraffa, Ivana Russo, Paolo Tini, Niccolo Giaj-Levra, Filippo Alongi, Giuseppe Minniti
Summary: This study evaluated the efficacy and toxicity of linear accelerator-based stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in patients with brainstem metastases. The results showed that this treatment approach provided excellent local control with low toxicity and no detrimental effects on overall survival. Concurrent targeted therapy may be associated with longer survival.
RADIATION ONCOLOGY
(2022)
Review
Oncology
Zhen Wang, Mohammed Nabhan, Steven E. Schild, Scott L. Stafford, Ivy A. Petersen, Robert L. Foote, M. Hassan Murad
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2013)
Letter
Oncology
Steven E. Schild, Sameer R. Keole, Robert L. Foote
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2013)
Article
Oncology
Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, Helen J. Ross, Rafat H. Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei
JOURNAL OF THORACIC ONCOLOGY
(2013)
Article
Oncology
D. Rades, L. Dziggel, B. Segedin, I. Oblak, V. Nagy, A. Marita, S. E. Schild, N. T. Trang, M. T. Khoa
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
N. D. Seibold, S. E. Schild, M. P. Gebhard, F. Noack, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
N. D. Seibold, S. E. Schild, M. P. Gebhard, F. Noack, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
D. Rades, T. Veninga, A. Bajrovic, J. H. Karstens, S. E. Schild
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Article
Oncology
L. Dziggel, B. Segedin, N. H. Podvrsnik, I. Oblak, S. E. Schild, D. Rades
STRAHLENTHERAPIE UND ONKOLOGIE
(2013)
Review
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Daniel F. Craft, Jarrod Lentz, Mike Armstrong, Madeline Foster, Justin Gagneur, Daniel Harrington, Steven E. Schild, Mirek Fatyga
PRACTICAL RADIATION ONCOLOGY
(2020)
Correction
Oncology
Ronald Chow, Peter Hoskin, Steven E. Schild, Srinivas Raman, James Im, Daniel Zhang, Stephanie Chan, Nicholas Chiu, Leonard Chiu, Henry Lam, Edward Chow, Michael Lock
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Steven E. Schild, Xiaofei Wang, Christine M. Bestvina, Terence Williams, Greg Masters, Anurag K. Singh, Thomas E. Stinchcombe, Joseph K. Salama, Steven Wolf, Tyler Zemla, Narjust Duma, Stephen G. Chun, Arya Amini, David Kozono, Colleen Watt
Summary: This study aims to determine if stereotactic body radiation therapy (SBRT) added to systemic therapy can significantly improve outcomes for patients with advanced stage non-small cell lung cancer (NSCLC) without PD-L1 protein expression. The trial will compare SBRT plus systemic therapy with systemic therapy alone and evaluate progression-free and overall survival. This multi-institutional trial will provide further insight into the efficacy of combining SBRT with systemic therapy.
CLINICAL LUNG CANCER
(2022)
Review
Oncology
R. S. Bhangoo, T. W. Cheng, M. M. Petersen, C. S. Thorpe, T. A. DeWees, J. D. Anderson, C. E. Vargas, S. H. Patel, M. Y. Halyard, S. E. Schild, W. W. Wong
Summary: This article characterizes radiation recall dermatitis (RRD), a skin reaction triggered by subsequent systemic therapy, and compares the most common drug classes implicated in this phenomenon.
SEMINARS IN ONCOLOGY
(2022)
Article
Biology
Dirk Rades, Cansu Delikanli, Steven E. Schild, Charlotte Kristiansen, Soren Tvilsted, Stefan Janssen
Summary: Decisions regarding personalized treatment for brain metastases should consider the patient's estimated lifespan, which can be determined using survival scores. In a study of very elderly patients (>= 80 years) with brain metastases who underwent whole-brain radiotherapy, a new survival score showed higher accuracy in predicting death and survival compared to an existing tool. The new score appears to be preferable, but further validation is needed.
Article
Oncology
William W. Wong, Eric M. Anderson, Homan Mohammadi, Thomas B. Daniels, Steve E. Schild, Sameer R. Keole, C. Richard Choo, Katherine S. Tzou, Alan H. Bryce, Thai H. Ho, Fernando J. Quevedo, Sujay A. Vora
CLINICAL GENITOURINARY CANCER
(2017)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
